Skip to main content
Journal ArticleOPEN ACCESS

Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma

  • Alderuccio J
  • Desai A
  • Yepes M
  • et al.
Clinical Case Reports (2018) 6(4) 634-637
DOI: 10.1002/ccr3.1382
N/ACitations
Citations of this article
27Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeutic modality for patients with BIA‐ALCL.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Alderuccio, J. P., Desai, A., Yepes, M. M., Chapman, J. R., Vega, F., & Lossos, I. S. (2018). Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma. Clinical Case Reports, 6(4), 634–637. https://doi.org/10.1002/ccr3.1382

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 8

80%

Researcher 2

20%

Readers' Discipline

Tooltip

Medicine and Dentistry 14

70%

Nursing and Health Professions 3

15%

Agricultural and Biological Sciences 2

10%

Engineering 1

5%

Save time finding and organizing research with Mendeley

Sign up for free